生物技术
Search documents
神秘的899条款--详解特朗普“大漂亮”法案隐藏的“资本税”
Hua Er Jie Jian Wen· 2025-06-04 00:48
Group 1: Core Insights - The "mysterious 899 clause" in U.S. tax law may escalate trade tensions into a capital war, imposing punitive tax burdens of up to 20% on foreign investors, particularly targeting countries like the EU that do not comply with U.S. trade demands [1][3] - Major Wall Street institutions warn that this clause could fundamentally alter the tax treatment of foreign capital in the U.S., being described as a "nuclear option" by the Trump administration [1][3] Group 2: Details of the 899 Clause - The 899 clause, officially known as "Enforcement Measures Against Unfair Foreign Taxes," is part of the recently passed "One Big Beautiful Bill Act" [2] - It aims to impose retaliatory taxes on non-U.S. individuals, companies, and governments from countries deemed to impose "unfair/discriminatory" taxes on U.S. entities [3] Group 3: Definition of "Discriminatory" Taxes - "Discriminatory" taxes include Digital Services Taxes (DST), Digital Profit Taxes (DPT), and low-tax profit rules under the OECD's global minimum tax framework [4] - The U.S. opposes the OECD framework, arguing it disproportionately affects American companies with significant global influence [4] Group 4: Tax Implications - The 899 clause could raise the statutory tax rate on U.S.-sourced income from interest, dividends, rents, and royalties by up to 20 percentage points for countries considered "discriminatory," increasing by 5 percentage points annually [5] - Investment portfolio interest may be exempt, but non-U.S. financial institutions relying on treaty-based exemptions could still be affected [6] Group 5: Revenue Projections - The 899 clause is expected to generate approximately $120 billion in tax revenue over ten years, equating to an annual increase of $12 billion, which is relatively minor compared to the overall U.S. tax landscape [7] Group 6: Impact on U.S. Deficit - The clause may influence foreign demand for U.S. assets, potentially helping to reduce the current account deficit, although rising yields could offset some revenue gains [8] Group 7: Legislative Uncertainty - There is uncertainty regarding the passage of the 899 clause in the Senate due to potential jurisdictional issues and the delegation of tax powers to the executive branch [9] Group 8: Affected Companies - Goldman Sachs has begun assessing the risk exposure of EU companies to the 899 clause, creating a "GS EU 899 Clause Basket" that includes firms with significant U.S. sales [10] - The basket consists of companies with an average U.S. sales exposure of about 48%, while excluding those with high U.S. ownership [10] Group 9: Market Performance and Valuation - Despite better earnings expectations for the GS EU 899 Clause Basket compared to the GS Domestic Quality Basket, its performance has weakened since early May, with current valuations still above historical ranges [12] - High trading congestion and negative earnings momentum for the GS EU 899 Basket suggest continued pressure on performance [14]
深度 | 限制对华投资,美国有哪些手段?—— “特朗普经济学”系列之十六【陈兴团队·财通宏观】
陈兴宏观研究· 2025-06-03 13:41
核 心 观 点 在特朗普上任伊始,就签署了《美国优先投资政策》总统备忘录,旨在进一步限制中美之间的投资往来,并鼓励盟友投资。那么,《美国优先投资政策》到底 该如何理解?又会带来怎样的影响? 美国对华投资限制,在哪些方面? 与现行规则相比,《美国优先投资政策》备忘录强化了 三项重要措施。一是扩大限制美对中投资范围与类型 ,将对外投 资审查范围扩大,从半导体、量子和人工智能三个行业, 扩大至生物技术、高超音速、航空航天、先进制造、定向能源以及中国国家军民融合战略涉及的领 域 。同时,考虑将公开交易证券纳入限制。 二是扩大外国投资委员会(CFIUS)的审查权限,加强审查中对美投资。三是考虑终止1984《中美所得税协 定》。 在限制投资政策的落实中, 美国财政部既负责制定规则,也是执行制裁的主导者 。其下属部门中, OFAC和CFIUS负责审查外国对美投资 ,CFIUS负 责审查外国投资美国战略部门的交易。投资限制发端于特朗普第一任期,并在拜登任期内强化。从落地程序来看, 限制中美投资往来的细则待财政部制定, 具体规则最快或在一个季度内出台,最晚可能在年底前 ;中概股最早可能在2026年年中面临退市风险;终止中美所得 ...
BioNTech美股盘前一度涨近12%
news flash· 2025-06-03 12:14
BioNTech美股盘前一度涨近12%,该公司前一交易日收涨超18%。跨国医药巨头百时美施贵宝宣布,与 德国生物技术公司BioNTech就新一代抗癌药物BNT327达成授权协议,协议的里程碑付款最高可达111 亿美元。 ...
一种由AI开发的肺病药物在临床试验中显示出“最佳治疗结果”
news flash· 2025-06-03 10:04
一种由AI开发的肺病药物在临床试验中显示出"最佳治疗结果" 金十数据6月3日讯,一种利用人工智能开发的药物在治疗一种无法治愈的肺部疾病方面显示出疗效,其 开发者称这是临床首例。生物技术公司英矽智能(Insilico Medicine)表示,这是人工智能创造、由人 工智能确定研究方法的药物首次通过中期临床研究。根据周二发表在《自然医学》上的一篇论文,一小 群特发性肺纤维化(肺瘢痕导致呼吸困难)患者在服用最高剂量的Rentosertib药物后,肺功能得到改 善。生物标志物分析显示,这种药物在分子水平上的作用完全符合预期,切断了人工智能假设的与疾病 有关的蛋白质。Insilico首席执行官Alex Zhavoronkov在接受采访时说,"这是人们见过的最好的治疗结 果之一"。 ...
【活动预告】Q Bay Center 2025年度杭州行活动即将举行,分享论坛与全球路演报名开启!
3 6 Ke· 2025-06-03 09:27
在全球科技创新加速融合的背景下,Q Bay Center聚焦构建国际科技产业协同创新生态。中心计划于 2025年6月12日-13日组织"重塑合作:全球视野下的中美交流与新机遇" 杭州行活动。 Q Bay Center 205 本次活动聚焦技术、资本与人才三大核心要素,搭建高效对接平台,推动优质科技项目落地、融资和发展。核心目标是展现杭州的经济发展环境和丰富资 源,同时搭建桥梁,连接寻求国际扩展的江浙企业,寻找市场合作契机,以促进全球范围内科技创新的交流与合作。 在为期两天的活动中,参会者将有机会全面洞悉亚太和北美的商业环境及政策走向,探讨双边合作的广阔天地。此次活动不仅将助力亚太企业顺利融入国 际市场,北美企业获得亚太市场发展机遇,同时也将共同孵化前瞻性的国际合作项目,一同沿着开放创新的轨迹开拓机遇无限的未来。 活动议程 活动地点:国际创博中心会议厅(钱塘区新加坡科技园路267号二楼) 活动时间:上午9:30 - 下午18:00 指导单位:钱塘区委组织部、钱塘区人力社保局(区委编办)、医药港管理办公室、大创小镇管理办公室 主办单位:杭州市人才集团有限公司、杭州钱塘新区产业发展集团有限公司 执行单位:杭州海外创 ...
再加码!实体清单“50%规则”子公司穿透
是说芯语· 2025-05-31 00:12
以下文章来源于东不压桥研究院 ,作者南极土著 东不压桥研究院 . 关注地缘政治竞争中的科技政策与数字治理,仅代表个人观点,与作者所在的组织无关。 今天彭博社发布报道,透露美国政府计划借鉴财政部外国资产控制办公室(OFAC)针对SDN清单主体子公司 的"50%规则",规定: 上了商务部实体清单的公司持股50%及以上的子公司,也受到和实体清单企业等同的出 口管制。 DeepSeek 通过马来西亚和新加坡这些第三国绕过美国严格的出口管制,获取了先进的英伟达芯片,你打算怎么 解决这个问题。 OFAC的"50%规则"是判断下属公司是否受到制裁的重要标准。具体而言:如果某一被列入SDN(特别指定国 民)清单的实体,直接或间接持有另一家公司50%或以上的股份或权益(包括投票权),那么该下属公司即使 没有被单独列名,也会被视为SDN实体,同样受到制裁。 此外,如果多家SDN清单上的实体共同直接或间接持有某公司50%以上的股份或权益,那么该公司同样被视作 SDN。这种情形在实际操作中常常涉及交叉持股、多层级持股等复杂股权结构,是"50%规则"实务适用中的难 点。 根据彭博社的这个报道,"知情人士"透露:美国官员正在起草一项规定 ...
Summit(SMMT.US)与康方生物合作药物3期试验获积极结果,有望冲刺FDA申报
智通财经网· 2025-05-30 12:37
Core Insights - Summit Therapeutics announced that its main asset ivonescimab, developed in collaboration with Chinese partner Kangfang Biopharma, achieved its primary endpoint in a clinical trial for lung cancer treatment [1][2] - The phase 3 HARMONi trial demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) when ivonescimab was combined with chemotherapy, although the overall survival (OS) did not show statistically significant differences [1] - The trial focused on patients with locally advanced or metastatic non-squamous non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, who are resistant to third-generation EGFR tyrosine kinase inhibitors [1] Trial Results - The HARMONi trial showed that approximately 57% of patients receiving ivonescimab plus chemotherapy experienced grade 3 or higher treatment-related adverse events, compared to about 50% in the control group [1] - The results align with the HARMONi-A trial conducted in China, which led to the approval of ivonescimab combined with chemotherapy for lung cancer treatment by Chinese regulatory authorities [2] Regulatory Plans - Summit plans to utilize the HARMONi trial data to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ivonescimab in combination with chemotherapy for the specified lung cancer patient population [2] Market Reaction - Following the announcement, Summit's stock experienced volatility, initially rising over 16% before dropping more than 12% in pre-market trading [3]
易瑞生物: 第三届董事会第十一次会议决议公告
Zheng Quan Zhi Xing· 2025-05-30 11:09
Group 1 - The company held its 11th meeting of the 3rd Board of Directors on May 30, 2025, with all 7 directors present, ensuring compliance with legal and regulatory requirements [1][2] - The Board approved a proposal to expand the business scope to include "inspection and testing services" to meet operational needs [1][2] - As of May 29, 2025, the company's total share capital increased from 400,865,155 shares to 401,317,665 shares due to the conversion of convertible bonds, leading to a corresponding increase in registered capital [1][2] Group 2 - The proposal requires approval from the shareholders' meeting, needing a two-thirds majority of the voting rights present [2] - The company plans to hold its first extraordinary shareholders' meeting of 2025 on June 16, 2025, to discuss the proposal [2]
礼来收购非阿片类疼痛疗法初创公司SiteOne
Jing Ji Guan Cha Bao· 2025-05-29 02:19
Core Insights - Eli Lilly has reached a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company focused on developing sodium channel small molecule inhibitors for pain and other neuronal hyperexcitability disorders, with shareholders potentially receiving up to $1 billion in cash [1][2] Group 1: Acquisition Details - The acquisition includes STC-004, a Nav1.8 inhibitor currently in Phase 2 clinical preparation for pain treatment, which may represent a new generation of non-opioid chronic pain therapies [1] - SiteOne shareholders will receive up to $1 billion in cash, which includes upfront payments and subsequent payments contingent upon achieving certain regulatory and commercial milestones [1] Group 2: Company Vision and Commitment - SiteOne has dedicated over a decade to advancing a vision of providing safer and more effective non-opioid therapies for patients suffering from pain and other sensory hyperexcitability disorders [2] - The CEO of SiteOne expressed confidence that Eli Lilly's global capabilities and leadership in neuroscience will accelerate the realization of STC-004 and the broader platform's potential [2]
港股生物技术板块拉升,药明巨诺(02126.HK)涨11.7%,药明合联(02268.HK)涨7.34%,药明生物(02269.HK)涨6.85%,君实生物(01877.HK)涨近6%。
news flash· 2025-05-29 01:59
Group 1 - The biotechnology sector in Hong Kong has seen a significant rally, with notable stock price increases for several companies [1] - WuXi AppTec (02126.HK) experienced an 11.7% increase in its stock price [1] - WuXi Biologics (02269.HK) and Junshi Biosciences (01877.HK) also saw substantial gains, with increases of 6.85% and nearly 6% respectively [1] - WuXi AppTec's subsidiary, WuXi Biologics (02268.HK), rose by 7.34% [1]